Monte Rosa Therapeutics, Inc. GLUE Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s other income (expense)?
- Monte Rosa Therapeutics, Inc. (GLUE) reported other income (expense) of $5.58M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s other income (expense) changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s other income (expense) increased by 52.1% year-over-year, from $3.67M to $5.58M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s other income (expense)?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s other income (expense) has grown at a 91.5% compound annual growth rate (CAGR), from -$1.08M to $14.49M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.